Skip to content

Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells

Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00801333
Enrollment
25
Registered
2008-12-03
Start date
2008-11-30
Completion date
2030-12-31
Last updated
2025-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis

Keywords

ALS

Brief summary

Induced pluripotent stem cells potentially may be useful in the future as an unlimited source of cells for transplantation. The major goal of the project is to develop human iPS cells from various types of cell cultures or lines from existing collections. The IPS cells will be developed for modeling diseases, for developing the technology that may eventually allow the use of IPS cells for transplantation therapy, and for basic research.

Detailed description

The potential to reprogram somatic cells into an embryonic state raises multiple basic research questions related both to the process of reprogramming and the properties of iPS cells. We will use various approaches to study the molecular mechanisms and processes that occur during reprogramming. We will use various experimental systems to characterize and study the properties of the iPS cells, their biology, developmental potential, capability to give rise to functional differentiated progeny etc. We will induce the differentiation of the iPS cells towards specific cell lineages and the progeny can be used to study the pathogenesis of diseases. They will be used for developing new therapeutic approaches and for high throughput screening of factors for potential toxic or therapeutic effects. All samples will be non-identified.

Interventions

None listed

Sponsors

Hadassah Medical Organization
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Volunteers * Male and Female

Exclusion criteria

* Below the official age of consent

Countries

Israel

Contacts

Primary ContactBenjamin E. Reubinoff, M.D. PhD.
benjaminr@ekmd.huji.ac.il011-972-2-677-4569
Backup ContactShelly E Tannenbaum, MSQA
stannenbaum@hadassah.org.il011-972-2-677-7945

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026